|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,518 JPY | +1.88% |
|
-2.60% | +2.15% |
TOKYO (Reuters) - Fujitsu Ltd, Mizuho Financial Group Inc, and drugmaker PeptiDream Inc said on Thursday they are forming a joint venture to develop treatments for COVID-19.
The new company, to be called PeptiAID Inc, will research and develop peptide therapeutics for the current SARS-CoV-2 virus and potential future coronavirus outbreaks, the companies said in a release.
The joint venture also includes Takenaka Corp and Kishida Chemical Co.
(Reporting by Rocky Swift; Editing by Kim Coghill)
Price
|
Change
|
5d. change
|
Capi.
| ||
|---|---|---|---|---|---|
| 2,970 JPY | +1.47% | -0.25% | 47.98B | ||
| 2,470 JPY | -0.92% | +0.12% | 29.66B | ||
| 1st Jan change | Capi. | |
|---|---|---|
| +2.15% | 1.25B | |
| -3.30% | 102B | |
| +1.79% | 96.84B | |
| -0.44% | 21.48B | |
| -18.35% | 20.82B | |
| -7.45% | 18.6B | |
| -40.31% | 16.81B | |
| -26.84% | 13.78B | |
| +0.59% | 13.4B | |
| +20.86% | 11.06B |
PEPTIDREAM INC. 
